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Triad of Metabolic Syndrome, Chronic Kidney Disease, and
Coronary Heart Disease With a Focus on Microalbuminuria
Death by Overeating
Freij Gobal, MD,* Abhishek Deshmukh, MD,* Sudhir Shah MD,† Jawahar L. Mehta, MD, PHD*
Little Rock, Arkansas
Coronary heart disease remains a major cause of morbidity and mortality in the United States, and its incidence
is rising worldwide. Because atherosclerosis is a chronic process, and it is often associated with certain lifestyle
and risk factors such as hypertension, dyslipidemia, and insulin resistance, much emphasis is being placed on
lifestyle modification and control of risk factors. It is being recognized that some lifestyle patterns such as over-
eating result in metabolic syndrome, which may play a role in the development of chronic kidney disease and
coronary heart disease. Here, we focus on an important relationship between these 3 conditions, and we provide
evidence that microalbuminuria develops in many patients with metabolic syndrome, may be an important cor-
relate of chronic kidney disease and coronary heart disease, and may represent an important prognostic marker.
Although the pathogenesis of microalbuminuria in metabolic syndrome is not clear, we suggest that microalbu-
minuria, chronic kidney disease, and coronary heart disease share common pathways involving inflammation
and oxidative stress. We also discuss that a healthy lifestyle is essential for preventing and treating chronic kid-
ney disease and coronary heart disease seen in patients with metabolic syndrome. (J Am Coll Cardiol
2011;57:2303–8) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.027There is emerging evidence for the association, interaction,
and multiplier effect between metabolic syndrome, chronic
kidney disease, and coronary heart disease. Microalbumin-
uria is a relatively common accompaniment of metabolic
syndrome and may be a marker for the development of
chronic kidney disease and coronary heart disease (1). Here,
we discuss our current understanding of the interaction of
metabolic syndrome, chronic kidney disease, and coronary
heart disease. Based on this understanding, it may be
possible to intervene with lifestyle modification alone or
with medications to prevent deadly complications of meta-
bolic syndrome.
Metabolic Syndrome and Microalbuminuria
The term metabolic syndrome refers to the presence of several
ardiovascular risk factors in the same subject (2). These
nclude abdominal obesity (waist circumference 40 inches
in men and 35 inches in women), insulin resistance
(fasting blood glucose 100 mg/dl or drug treatment for
elevated blood glucose), hypertension (blood pressure
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2011, accepted February 15, 2011.130/85 mm Hg or drug treatment for elevated blood
pressure), and dyslipidemia (triglycerides 150 mg/dl and
high-density lipoprotein [HDL] cholesterol 40 mg/dl in
men and 50 mg/dl in women or drug treatment for high
triglycerides or low HDL cholesterol).
Although it has been termed a syndrome or a disease-
state, the prevalence of metabolic syndrome has risen
dramatically in all wealthy societies over the past 2 decades
(3). Its prevalence is increasing rapidly in the newly rich
countries of Asia, South America, and Eastern Europe. The
rising prevalence of metabolic syndrome in proportion to
wealth could simply be a manifestation of overconsumption of
calories and/or their underutilization. This syndrome seems to
affect all races, both men and women, and even children, and
it has a role in the causation of many disease states.
In the Finnish diabetic subjects, metabolic syndrome was
associated with an increased risk of microalbuminuria (4),
defined as urinary albumin–creatinine ratio 30 to 300 mg/g.
In the Framingham Offspring Study, urinary albumin–
creatinine ratio was elevated in the presence of each com-
ponent of metabolic syndrome (5). Microalbuminuria, how-
ever, was more common in subjects who had constellation of
all 3 components of metabolic syndrome than in those
without (6).
Hypertension is associated with an approximately 2- to
3-fold increased risk of microalbuminuria (7). Microalbumin-
uria in hypertension is perhaps related to increased intraglo-
merular pressure and resultant injury to the epithelial lining
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Microalbuminuria is an early
marker of renal dysfunction due to
hypertension, especially among
young African Americans (9), and
predicts the onset of kidney disease
in diabetic and nondiabetic sub-
jects (10).
Although hyperglycemia is
well documented to be associated
with albuminuria (11,12), it is
unclear whether lipid abnormal-
ities have an independent role in
the genesis of microalbuminuria
(13). Body mass index, a marker
of metabolic syndrome, is a sur-
rogate for total body fat; how-
ever, there is little published in-
formation on the relationship
between microalbuminuria and
total or regional body fat (14). In
ddition, the metabolic abnormalities associated with mi-
roalbuminuria predict cardiovascular morbidity and mor-
ality (15,16).
echanisms of Microalbuminuria
n Metabolic Syndrome
he precise pathogenetic basis of microalbuminuria in
etabolic syndrome is not known; it is, however, possible
hat microalbuminuria in metabolic syndrome reflects
enin-angiotensin system activation and resultant oxidant
tress and inflammation.
Several investigators have shown that hypertension, dys-
ipidemia, and insulin resistance are associated with renin-
ngiotensin system activation and generation of large
mounts of angiotensin II (Ang II) (17,18). Ang II via its
ype 1 (AT1) receptor is a potent activator of reduced
icotinamide adenine dinucleotide phosphate (NADPH)
xidase in various tissues and circulating cells, such as
eukocytes and platelets (19). The NADPH oxidase system
s the most potent reactive oxygen species (ROS)-
enerating system in vascular tissues. The NADPH oxidase
s composed of membrane-bound gp91phox and p22phox, as
well as cytosolic subunits such as p47phox, p67phox, and small
uanosine triphosphate Rac. The molecular mechanism of
ADPH oxidase activation in endothelial cells is best
haracterized for the Nox2-based oxidase and Nox1. In
eneral, Nox2 oxidase activation involves translocation of
ytosolic oxidase components (p47phox, p67phox, and
uanosine triphosphate Rac) to the plasma membrane and
ssociation with cytochrome b558, which initiates the elec-
ron transfer process (20).
Native low-density lipoprotein (LDL) cholesterol is ox-
dized by ROS, resulting in the formation of oxidized-
Abbreviations
and Acronyms
Ang II  angiotensin II
AT1  angiotensin II type 1
HDL  high-density
lipoprotein
LDL  low-density
lipoprotein
LOX-1  lectin-like
oxidized–low-density
lipoprotein
NADPH  reduced
nicotinamide adenine
dinucleotide phosphate
ox-LDL  oxidized low-
density lipoprotein
ROS  reactive oxygen
species
TNF  tumor necrosis
factorow-density lipoprotein (ox-LDL). As was recently re- piewed (21), ox-LDL is more important in atherogenesis
han is native LDL. Plasma levels of ox-LDL levels are
levated in patients with hypertension, dyslipidemia, and
iabetes, and those with chronic kidney disease and coro-
ary heart disease (22,23). Further, ROS are potent pro-
nflammatory molecules that act as chemoattractants for
nflammatory cells, induce endothelial injury (24), scavenge
he vasodilator species nitric oxide, and cause platelets and
eukocytes to aggregate (25,26). These observations suggest
n important relationship between oxidant stress and in-
ammation. ROS can induce the expression of lectin-like
xidized–low-density lipoprotein (LOX-1) receptors (27),
ound predominantly on endothelial cells, but also on
latelets, vascular smooth muscle cells, and renal tissues
28). LOX-1 is up-regulated by ox-LDL, tumor necrosis
actor (TNF)-alpha, Ang II, and shear stress (28). LOX-1
ctivation per se can stimulate ROS generation (28), which
uggests a positive feedback loop between ROS and
OX-1. Whether ROS up-regulates other scavenger recep-
ors for ox-LDL is currently unknown.
Li et al. (29) showed that AT1 receptor activation causes
OX-1 up-regulation and induces ox-LDL internalization
n endothelial cells. These investigators (30) also showed
hat ox-LDL via LOX-1 up-regulates the expression of
T1 receptors, suggesting a positive feedback loop among
he renin-angiotensin system, ROS, and LOX-1 (Fig. 1).
oth dyslipidemia and hypertension induce fibroblast
rowth and collagen synthesis (31). Hyperglycemia also
timulates collagen synthesis (32).
The role of LOX-1 in hypertension and the genesis of
ardiac and renal disease became evident from the work of
u et al. (33,34). They infused mice with Ang II for 28
ays, which caused blood pressure to rise and hearts and
idneys to develop changes consistent with long-standing
ypertension. These alterations of cardiac and renal remod-
ling were markedly attenuated in mice lacking the LOX-1
ene. Others have shown salutary effects of AT1-receptor
lockers in animal models of hypertension. Incidentally,
T1-receptor blockers reduce endothelial injury, ROS-
eneration, and atherogenesis (35). There is also a sugges-
ion that weight loss in obese rodents reduces blood pres-
ure, evolution of insulin resistance, inflammation, and
xidant stress (36,37).
These observations in different model systems suggest a
lose interaction among the components of metabolic syn-
rome, that is, hypertension, dyslipidemia, and insulin
esistance, mediated via redox-sensitive pathways, and the
enin-angiotensin system and LOX-1 activation.
There is also an important role for redox-sensitive tran-
cription factors, such as nuclear factor kappa B, in ROS-
ediated inflammation (30). Nuclear factor kappa B up-
egulation correlates with the degree of albuminuria in
iabetic patients (38). Activation of nuclear factor kappa B
romotes the expression of proinflammatory cytokines, such
s TNF-alpha and interleukin-6, which in turn trigger the
roduction of C-reactive protein. This association may
2305JACC Vol. 57, No. 23, 2011 Gobal et al.
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syndrome (38). The blockade of TNF-alpha by the soluble
TNF-alpha receptor has been shown to ameliorate albu-
minuria in a rat model of glomerulonephritis (39). Thus,
endothelial dysfunction, oxidant load, and inflammation
may be important factors linking albuminuria to metabolic
syndrome and evolution of coronary heart disease risk (40)
(Fig. 1).
Chronic Kidney Disease, Microalbuminuria,
and Metabolic Syndrome
Cross-sectional studies have shown a relationship between
metabolic syndrome and chronic kidney disease (41,42).
Chen et al. (42), for instance, found a 2.6-fold increase in
the prevalence of chronic kidney disease among adults with
metabolic syndrome in the NHANES III (Third National
Health and Nutrition Examination Study). In the ARIC
(Atherosclerosis Risk In Communities) study (43), patients
with metabolic syndrome without overt diabetes were found
to have an increased risk for chronic kidney disease over 9
years of follow-up.
This association may be explained on many levels. Obe-
Figure 1
Postulated Mechanism of Microalbuminuria
as a Correlate of Chronic Kidney Disease and
Coronary Heart Disease in Metabolic Syndrome
The activation of angiotensin II (Ang II) type 1 receptor (AT1R) and its interac-
tion with oxidized low-density lipoprotein (ox-LDL) leads to oxidant load and
inflammation. The pathways include activation of reduced nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase, lectin-like oxidized–low-density lipo-
protein (LOX-1) and redox-sensitive signaling pathways. This results in endothe-
lial cells (EC) injury, atherosclerosis, and tissue fibrosis. Figure illustration by
Craig Skaggs. AP1  activating protein 1; ERK  extracellular signal-regulated
kinase; JNK  Jun N-terminal kinase; MAPK  mitogen-activated protein
kinase; NF-B  nuclear factor kappa B; ROS  reactive oxygen species;
TF  transcription factor; TNF  tumor necrosis factor.sity has been implicated in the development of focalsegmental glomerulosclerosis and glomerulomegaly (44,45),
and kidney disease (46). Weisinger et al. (44) first reported
massive proteinuria associated with obesity. Subsequent
reports have confirmed the presence of proteinuria and
glomerulomegaly in obese subjects (47,48). In animal stud-
ies, the feeding of a high-fat diet for a few weeks led to
glomerulomegaly with Bowman’s capsule expansion, glo-
merular cell proliferation, mesangial matrix expansion, and
glomerular and tubular basement membrane thickening
(49). Several mechanisms, acting singly or in combination
linking obesity to chronic kidney disease, have been pro-
posed; these include: 1) renal adaptation to increased body
mass, resulting in increased excretory load; 2) sodium
retention; 3) insulin resistance; and 4) renal lipotoxicity
(50,51). Chagnac et al. (52) showed renal hyperperfusion
and increased filtration in morbid obesity. The reduced
renal resistance with hyperfiltration was consistent with
total afferent loop dilation and glomerular capillary hyper-
tension, the classic recipe for eventual glomerulosclerotic
damage. Furthermore, in keeping with glomerular hyper-
tension, the first clinical evidence of renal disease in obesity
is proteinuria (53).
Dyslipidemia has also been liked to chronic kidney
disease. A recent meta-analysis suggests that elevated trig-
lycerides and low HDL cholesterol in plasma are indepen-
dent risk factors for the development of chronic kidney
disease (54), and that use of statins may slow the progres-
sion of chronic kidney disease (55). In the Modification of
Diet in Renal Disease Study, low plasma HDL cholesterol
level independently predicted renal disease progression (56).
In the ARIC study, Muntner et al. (57) found that high
triglycerides and low HDL cholesterol in plasma signifi-
cantly increased the probability of developing renal dysfunc-
tion. A well-documented form of multiorgan injury
associated with metabolic syndrome is lipotoxicity (58).
Lipotoxicity in proximal tubular cells with associated local
inflammation is now a recognized consequence of protein-
uria (59).
Hypertension and diabetes, both components of meta-
bolic syndrome, are known to be associated with renal
dysfunction. The pathophysiology of chronic kidney disease
in hypertensive and diabetic patients likely involves oxida-
tive stress and inflammation mediated by renin-angiotensin
system activation. Clinical trials have shown the benefit of
treatment of hypertension and diabetes in reducing the risk
of developing kidney disease. Intensive exercise and weight
loss in individuals with metabolic syndrome result in im-
provement in renal function (60). Pharmacologic interven-
tions with angiotensin-converting enzyme inhibitors and
AT1-receptor blockers improve insulin sensitivity (61) and
ameliorate microalbuminuria in addition to their well-
documented cardio- and reno-protective effects (62). Data
in veteran patients showed that the use of statins delayed the
progression of renal dysfunction (63). This effect appeared
to be independent of change in cholesterol levels. Met-
formin, unfortunately, is contraindicated in patients with
2306 Gobal et al. JACC Vol. 57, No. 23, 2011
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in preventing development of diabetes in pre-diabetic indi-
viduals (64).
Coronary Heart Disease, Microalbuminuria,
and Metabolic Syndrome
Microalbuminuria is considered an independent predictor of
cardiovascular and all-cause mortality in patients with and
without diabetes (65). In the EPIC-Norfolk (European
Prospective Investigation of Cancer-Norfolk Study), inci-
dence of coronary heart disease increased significantly with
baseline albuminuria. Microalbuminuria predicted primary
coronary heart disease events independent of other risk
factors. This study also showed increased mortality in
patients with myocardial infarction who had microalbumin-
uria (66). Investigators in the HOPE (Heart Outcomes
Prevention Evaluation) study made a similar observation
(10). The relationship between microalbuminuria and cor-
onary heart disease is independent of sex, age, and race. For
example, an increased albumin-creatinine ratio predicted
coronary heart disease among the Danish population in the
multinational MONICA (Monitoring of Trends and De-
terminants in Cardiovascular Disease) study, a population-
based study of nondiabetic persons (1). This observation is
consistent with the observations in another population-
based study of elderly nondiabetic subjects in Finland (16),
as well as in the DOM (Diagnostisch Onderzoek Mam-
macarcinoom) study of post-menopausal women in the
Netherlands (67).
The precise basis of the association of microalbuminuria
and atherosclerosis is unclear. However, it may be mediated
through an increased generalized transvascular leakage of
albumin, in many ways similar to penetration of lipoproteins
(68). The enhanced “leakiness” might be due to hemody-
namic factors or structural perturbations in endothelial
integrity or the intracellular matrix beneath (69). Some
investigators have suggested that the association between
microalbuminuria, chronic kidney disease, and coronary
heart disease reflects widespread endothelial dysfunction
and microvascular damage and possibly inflammation (70)
(Fig. 2).
Microalbuminuria may be useful in identifying persons at
increased risk of coronary heart disease and subsequent
death. Therefore, in addition to Framingham score (71),
developing new scores for prediction of absolute risk of
primary coronary heart disease should include microalbu-
minuria (72,73). It is important to include microalbumin-
uria in cardiovascular disease risk assessment because pa-
tients with microalbuminuria, especially diabetic patients,
have much greater atherosclerotic burden than patients
without it (74). Accordingly, guidelines from the American
College of Cardiology and American Heart Association
now include microalbuminuria as a potent risk factor for the
development of coronary heart disease, as well as a poorprognostic marker in patients with pre-existing coronary
disease (75).
Treating patients with microalbuminuria more aggres-
sively for coronary heart disease may have important bene-
ficial effects. The HOPE study and the Micro-HOPE
substudy showed that treatment of persons at absolute risk
of cardiovascular disease, based on the presence of multiple
risk factors, including microalbuminuria, offers significant
primary and secondary prevention benefits (76,77). Re-
cently, the Steno Diabetes Centre Study (78) showed that
multifactorial intervention strategies, including behavior
modification and pharmacologic therapy targeting hypergly-
cemia, hypertension, dyslipidemia, and microalbuminuria,
lower the risk of cardiovascular disease by 50%. In the
PREVEND-IT (Prevention of Renal and Vascular End-
Stage Disease Intervention Trial), normotensive patients
with normal cholesterol levels and microalbuminuria were
randomly assigned to fosinopril or placebo and to pravasta-
tin or placebo (79). During the follow-up period of 4
years, fosinopril was associated with a trend toward a lower
rate of cardiovascular mortality and hospitalization (hazard
ratio: 0.6, 95% confidence interval: 0.33 to 1.10). In 2
post-hoc subset analyses of the LIFE (Losartan Interven-
tion for Endpoint Reduction) trial (80,81), losartan-treated
patients showed significant cardiovascular benefits.
Conclusions
Microalbuminuria, a predictor of progressive kidney disease
and a common accompaniment of metabolic syndrome, is a
significant marker of coronary heart disease and cardiovas-
cular and overall morbidity and mortality. This relationship
is seen early in patients with metabolic syndrome. Both
Figure 2 Interaction of Metabolic Syndrome,
Coronary Heart Disease, and Chronic Kidney Disease
Metabolic syndrome is associated with endothelial and epithelial injury result-
ing in proteinuria, coronary atherosclerosis, and chronic kidney disease. Figure
illustration by Craig Skaggs.microalbuminuria and metabolic syndrome could reflect
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stress and inflammation resulting in endothelial injury,
smooth muscle cell migration/proliferation, and later car-
diac and renal fibrosis.
Chronic renal disease has been linked to the high prevalence
of metabolic syndrome. It remains unclear whether metabolic
syndrome is a cause or a result of decreased kidney function
and whether this association is related to the presence of
diabetes. Nonetheless, awareness of this relationship and mak-
ing lifestyle changes (weight loss and excise) and using phar-
macologic interventions (lowering of blood pressure especially
with renin-angiotensin system modulators, antidiabetic treat-
ment, and dyslipidemia therapy) can delay or prevent the
complex triad of microalbuminuria, chronic kidney disease,
and coronary heart disease.
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